GMP IPO Watch
Baroda BNP Paribas Health and Wellness Fund
Direct Plan · Growth Option · Baroda BNP Paribas Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | -2.81% | -1.28% | 226 of 255 |
| 1M | -3.02% | -4.58% | 43 of 253 |
| 3M | -0.74% | -2.57% | 83 of 251 |
| 6M | +16.33% | +11.42% | 73 of 251 |
| YTD | +10.81% | -0.16% | 44 of 255 |
| 1Y | +10.57% | +2.02% | 52 of 228 |
| INCEPTION | +4.37% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +2.77% | +17.20% | -7.86% | 54% | 21% |
| 6M | +4.73% | +22.38% | -11.08% | 57% | 23% |
| 1Y | +10.09% | +15.01% | +3.99% | 100% | 43% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Aug 2026
Asset Allocation
- Equity98.78%
- Debt0.00%
- Cash0.20%
- Other1.02%
Market Cap Split
- Large Cap32.04%
- Mid Cap44.40%
- Small Cap19.89%
- Others3.67%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 41.60 | 42.86 |
| P/B | 7.59 | 6.43 |
| Price / Sales | 5.38 | 6.30 |
| Price / Cash Flow | 31.80 | 32.07 |
| Dividend Yield (%) | 0.64 | 0.59 |
Holdings · Aug 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 9.01% | +0.19% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 8.01% | +1.35% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 7.99% | -0.59% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 6.23% | +0.51% |
| Lupin | Pharmaceuticals & Biotechnology | 5.99% | -0.47% |
| Laurus Labs | Pharmaceuticals & Biotechnology | 5.66% | +0.42% |
| Apollo Hospitals | Equity | 5.44% | +0.09% |
| Fortis Healthcare | Equity | 4.50% | -0.05% |
| AstraZeneca Pharma | Pharmaceuticals & Biotechnology | 3.56% | -0.49% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.42% | -0.02% |
| Dr. Lal Path Labs | Equity | 3.24% | +0.12% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 3.10% | +0.01% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 3.05% | +0.01% |
| Max Financial Services | Insurance | 2.43% | +0.16% |
| Emcure Pharmaceuticals | Pharmaceuticals & Biotechnology | 2.38% | -0.08% |
View all 34 holdings
| Abbott | Pharmaceuticals & Biotechnology | 2.29% | -0.12% |
| Acutaas Chemicals | Pharmaceuticals & Biotechnology | 2.24% | +0.09% |
| Aster DM Quality Care | Equity | 2.23% | -0.30% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 2.15% | -0.32% |
| Concord Biotech | Pharmaceuticals & Biotechnology | 2.14% | +0.09% |
| Metropolis Healthcare | Equity | 1.49% | +0.03% |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 1.49% | +0.09% |
| Nephrocare Health Services | Equity | 1.35% | -0.39% |
| Manipal Health Enterprises | Equity | 1.27% | +0.31% |
| Symbiotec Pharmalab | Pharmaceuticals & Biotechnology | 1.18% | — |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 1.14% | +0.03% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 1.14% | -0.06% |
| Cipla | Pharmaceuticals & Biotechnology | 1.11% | -0.02% |
| Medplus Health Services | Retailing | 0.93% | -0.16% |
| Inventurus Knowledge Solutions | IT - Services | 0.85% | -0.57% |
| GlaxoSmithKline Pharmaceuticals | Pharmaceuticals & Biotechnology | 0.72% | — |
| Procter & Gamble Health | Pharmaceuticals & Biotechnology | 0.57% | -0.07% |
| LIC of India | Insurance | 0.48% | — |
| Net Receivables / (Payables) | Net Current Assets | 0.20% | — |
Sector Allocation · Aug 2026
Risk Metrics
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.56 | 1.00 | Poor Risk Adjusted Returns |
What is this?
Higher the value means that fund has been able to give better returns for the amount of risk taken. It helps investors understand the return of an investment compared to its risk, showing whether the returns are due to intelligent investing or simply taking on excess risk. It is calculated by subtracting the risk-free return, defined as an Indian Government Bond, from the fund's returns, and then dividing by the standard deviation of returns.
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.88 | 1.82 | Poor Risk Adjusted Returns |
What is this?
The Sortino Ratio is a financial metric used to measure the risk-adjusted return of an investment. It's a modification of the Sharpe Ratio but with a key difference; it only considers downside risk (the risk of negative returns), rather than total volatility. This means it focuses on how well an investment performs relative to the volatility that leads to losses, ignoring the volatility that results in gains. The idea is that investors are primarily concerned with minimizing losses, and positive volatility is generally seen as a good thing.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.84 | 0.94 | Good Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+125.07% | +61.55% | — | +32.55% |
|
Franklin Asian Equity Fund
Regular Plan · IDCW
|
+31.28% | +22.70% | +6.52% | +4.42% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+28.99% | +22.97% | +10.76% | +9.17% |
|
Motilal Oswal Active Momentum Fund
Direct Plan · Growth
|
+26.04% | — | — | +27.23% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.57% | +29.81% | — | +29.73% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+25.46% | — | — | +19.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+24.20% | — | — | +11.25% |
|
Motilal Oswal Special Opportunities Fund
Direct Plan · Growth
|
+19.68% | — | — | +19.59% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+19.63% | — | — | +8.42% |
|
Edelweiss Recently Listed IPO Fund
Regular Plan · Growth
|
+19.17% | +15.58% | +9.91% | +14.76% |
More From Baroda BNP Paribas Asset Management India Private Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Baroda BNP Paribas Gold ETF
Regular Plan · Growth Option
|
+25.19% | — | — | +34.68% |
|
Baroda BNP Paribas Gold ETF Fund of Fund
Direct Plan · Growth Option
|
+24.06% | — | — | +39.67% |
|
Baroda BNP Paribas Innovation Fund
Direct Plan · IDCW Option
|
+8.97% | — | — | +12.83% |
|
Baroda BNP Paribas Manufacturing Fund
Direct Plan · IDCW Option
|
+8.30% | — | — | +3.28% |
|
Baroda BNP Paribas Aqua Fund of Fund
Direct Plan · IDCW Option
|
+8.14% | +15.08% | — | +11.66% |
|
Baroda BNP Paribas Small Cap Fund
Direct Plan · Growth Option
|
+7.84% | — | — | +13.19% |
|
Baroda BNP Paribas Multi Asset Active Fund of Funds
Direct Plan · Growth Option
|
+7.44% | — | — | +9.58% |
|
Baroda BNP Paribas Credit Risk Fund (scheme has Two segregated portfolios)
Direct Plan · Growth Option
|
+7.05% | +8.36% | +9.33% | +8.73% |
|
Baroda BNP Paribas Ultra Short Term Fund
Direct Plan · Growth Option
|
+6.58% | +7.22% | +6.69% | +6.52% |
|
Baroda BNP Paribas Money Market Fund
Direct Plan · Growth Option
|
+6.52% | +7.26% | +6.50% | +5.89% |
About This Scheme
Investment Objective
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
Stated Asset Allocation
Equity & equity related instruments of companies in the Pharma & Healthcare and allied sector- 80-100%Equity and equity related instruments of companies other than above- 0-20%Money Market and other liquid instruments*, Gold and Silver instruments (through ETFs) - 0-20% Units of Mutual Funds as permitted by SEBI- 0-10% Units issued by InvITs - 0-10%
Exit Load
Redemption/ switch out of units upto 10% of the units allotted before 1 year from date of allotment- Exit load -NIL For redemption/switch out of units above 10% of units allotted within 1 year from the date of allotment- 1.00% of applicable NAV For redemption/switch out of units after 1 year from the date of allotment-Nil
Fund Managers
Mr. Rohan Korde, Mr. Ankeet Pandya
Primary, Primary
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.